Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cbd cannabidiol:

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. McGuire P et al. Am J Psychiatry. (2018)

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Burstein S et al. Bioorg Med Chem. (2015)

Neurological Aspects of Medical Use of Cannabidiol. Mannucci C et al. CNS Neurol Disord Drug Targets. (2017)

Search results

Items: 1 to 20 of 1283

1.

The role of time and storage conditions on the composition of hashish and marijuana samples: A four-year study.

Zamengo L, Bettin C, Badocco D, Di Marco V, Miolo G, Frison G.

Forensic Sci Int. 2019 Mar 8;298:131-137. doi: 10.1016/j.forsciint.2019.02.058. [Epub ahead of print]

PMID:
30901710
2.

Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors.

Jesus CHA, Redivo DDB, Gasparin AT, Sotomaior BB, de Carvalho MC, Genaro K, Zuardi AW, Hallak JEC, Crippa JA, Zanoveli JM, da Cunha JM.

Brain Res. 2019 Mar 18. pii: S0006-8993(19)30153-2. doi: 10.1016/j.brainres.2019.03.014. [Epub ahead of print]

PMID:
30898678
3.

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.

Akgün K, Essner U, Seydel C, Ziemssen T.

J Cent Nerv Syst Dis. 2019 Mar 11;11:1179573519831997. doi: 10.1177/1179573519831997. eCollection 2019. Review.

4.

Allergenic ingredients in commercial topical cannabinoid preparations.

Adler BL, DeLeo VA.

J Am Acad Dermatol. 2019 Mar 15. pii: S0190-9622(19)30429-3. doi: 10.1016/j.jaad.2019.03.015. [Epub ahead of print] No abstract available.

PMID:
30885758
5.

Cannabidiol: The Need for More Information About Its Potential Benefits and Side Effects.

Hande K.

Clin J Oncol Nurs. 2019 Apr 1;23(2):131-134. doi: 10.1188/19.CJON.131-134.

PMID:
30880812
6.

Liprin alfa 2 gene expression is increased by cannabis use and associated with neuropsychological function.

He Y, de Witte LD, Schubart CD, Van Gastel WA, Koeleman BPC, de Jong S, Ophoff RA, Hol EM, Boks MP.

Eur Neuropsychopharmacol. 2019 Mar 14. pii: S0924-977X(19)30192-0. doi: 10.1016/j.euroneuro.2019.03.004. [Epub ahead of print]

PMID:
30879928
7.

CBD as the New Medicine in the Pain Provider's Armamentarium.

Piermarini C, Viswanath O.

Pain Ther. 2019 Mar 12. doi: 10.1007/s40122-019-0117-1. [Epub ahead of print] No abstract available.

PMID:
30868477
8.

Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects.

Sekar K, Pack A.

F1000Res. 2019 Feb 28;8. pii: F1000 Faculty Rev-234. doi: 10.12688/f1000research.16515.1. eCollection 2019. Review.

9.

Influence of cosmetic hair treatments on cannabinoids in hair: Bleaching, perming and permanent coloring.

Van Elsué N, Yegles M.

Forensic Sci Int. 2019 Feb 26;297:270-276. doi: 10.1016/j.forsciint.2019.02.030. [Epub ahead of print]

PMID:
30851603
10.

Promoting cannabis products to pharmaceutical drugs.

Koltai H, Poulin P, Namdar D.

Eur J Pharm Sci. 2019 Mar 7;132:118-120. doi: 10.1016/j.ejps.2019.02.027. [Epub ahead of print]

PMID:
30851400
11.

Acute Cannabinoids Produce Robust Anxiety-Like and Locomotor Effects in Mice, but Long-Term Consequences Are Age- and Sex-Dependent.

Kasten CR, Zhang Y, Boehm SL 2nd.

Front Behav Neurosci. 2019 Feb 20;13:32. doi: 10.3389/fnbeh.2019.00032. eCollection 2019.

12.

Novel protective effect of O-1602 and abnormal cannabidiol, GPR55 agonists, on ER stress-induced apoptosis in pancreatic β-cells.

Vong CT, Tseng HHL, Kwan YW, Lee SM, Hoi MPM.

Biomed Pharmacother. 2019 Mar;111:1176-1186. doi: 10.1016/j.biopha.2018.12.126. Epub 2019 Jan 15.

13.

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.

Chye Y, Christensen E, Solowij N, Yücel M.

Front Psychiatry. 2019 Feb 19;10:63. doi: 10.3389/fpsyt.2019.00063. eCollection 2019. Review.

14.

Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.

Qian Y, Wang X, Markowitz JS.

Drug Metab Dispos. 2019 Mar 4. pii: dmd.118.086074. doi: 10.1124/dmd.118.086074. [Epub ahead of print]

16.

The Association between Cannabis Product Characteristics and Symptom Relief.

Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B.

Sci Rep. 2019 Feb 25;9(1):2712. doi: 10.1038/s41598-019-39462-1.

17.

DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor.

Silva RL, Silveira GT, Wanderlei CW, Cecilio NT, Maganin AGM, Franchin M, Marques LMM, Lopes NP, Crippa JA, Guimarães FS, Alves-Filho JCF, Cunha FQ, Cunha TM.

Toxicol Appl Pharmacol. 2019 Apr 1;368:63-71. doi: 10.1016/j.taap.2019.02.011. Epub 2019 Feb 20.

PMID:
30796934
18.

Detection of cannabinoids in hair after cosmetic application of hemp oil.

Paul R, Williams R, Hodson V, Peake C.

Sci Rep. 2019 Feb 22;9(1):2582. doi: 10.1038/s41598-019-39609-0.

19.

Cannabidiol modulates the expression of neuroinflammatory factors in stress- and drug-induced reinstatement of methamphetamine in extinguished rats.

Karimi-Haghighi S, Dargahi L, Haghparast A.

Addict Biol. 2019 Feb 22. doi: 10.1111/adb.12740. [Epub ahead of print]

PMID:
30793820
20.

Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders.

Krebs MO, Kebir O, Jay TM.

Eur J Pain. 2019 Feb 21. doi: 10.1002/ejp.1377. [Epub ahead of print] Review.

PMID:
30793421

Supplemental Content

Loading ...
Support Center